Pharmacological treatment of men with heart failure (HF) in Scotland, April 1999–March 2000
| Treatment | Age group (years) | ||||||
|---|---|---|---|---|---|---|---|
| 45–64 | 65–74 | 75–84 | ⩾85 | <75 | ⩾75 | All ages | |
| ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker. | |||||||
| Number | 64 | 132 | 164 | 74 | 201 | 238 | 439 |
| Furosemide | 36 | 80 | 114 | 49 | 119 | 163 | 282 |
| (56.3%) | (60.3%) | (69.5%) | (66.2%) | (59.2%) | (68.5%) | (64.2%) | |
| Any diuretic | 47 | 105 | 139 | 58 | 155 | 197 | 352 |
| (73.4%) | (79.6%) | (84.8%) | (78.4%) | (77.1%) | (82.8%) | (80.2%) | |
| ACE inhibitor | 39 | 71 | 69 | 21 | 111 | 90 | 201 |
| (60.9%) | (53.8%) | (42.1%) | (28.4%) | (55.2%) | (37.8%) | (45.8%) | |
| ARB | 4 | 5 | 8 | 1 | 9 | 9 | 18 |
| (6.3%) | (3.8%) | (4.9%) | (1.4%) | (4.5%) | (3.8%) | (4.1%) | |
| β Blocker | 20 | 34 | 33 | 14 | 55 | 47 | 102 |
| (31.3%) | (25.8%) | (20.1%) | (18.9%) | (27.4%) | (19.8%) | (23.2%) | |
| Spironolactone | 12 | 16 | 16 | 4 | 28 | 20 | 48 |
| (18.8%) | (12.1%) | (9.8%) | (5.4%) | (13.9%) | (8.4%) | (10.9%) | |
| Digoxin | 17 | 30 | 43 | 15 | 47 | 58 | 105 |
| (26.6%) | (22.7%) | (26.2%) | (20.3%) | (23.4%) | (24.4%) | (23.9%) | |
| Any HF treatment | 57 | 114 | 149 | 61 | 175 | 210 | 385 |
| (89.1%) | (86.4%) | (90.9%) | (82.4%) | (87.1%) | (88.2%) | (87.7%) | |